Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 5, 2017, Pages 681-687

  Elsharkawy, A ^a   Fouad, R ^a   El Akel, W ^a   El Raziky, M ^a   Hassany, M ^b   Shiha, G ^c   Said, M ^a   Motawea, I ^d   El Demerdash, T ^e   Seif, S ^b   Gaballah, A ^a   El Shazly, Y ^f   Makhlouf, M A M ^f   Waked, I ^g   Abdelaziz, A O ^a   Yosry, A ^a   El Serafy, M ^a   Thursz, M ^h   Doss, W ^a   Esmat, G ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL HEPATOLOGY AND TROPICAL MEDICINE RESEARCH INSTITUTE   (Egypt)

^c MANSOURA UNIVERSITY   (Egypt)

^d MINIA UNIVERSITY   (Egypt)

^e TANTA UNIVERSITY   (Egypt)

^f AIN SHAMS UNIVERSITY   (Egypt)

^g MENOUFIA UNIVERSITY   (Egypt)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; SOFOSBUVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; EGYPT; FEMALE; GENDER; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MULTICENTER STUDY;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EGYPT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR;

EID: 85009455162     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13923     Document Type: Article

References (26)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl 1): 74–81.
2. Waked I, Doss W, El-Sayed MH, et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol 2014; 15: 45–52. doi:10.1016/j.ajg.2014.04.003
3. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 2012; 19: 560–7. doi:10.1111/j.1365-2893.2011.01576.x
4. Gower E, Estes CC, Hindman S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus. J Hepatol 2014; 61: S45–57. doi:10.1016/j.jhep.2014.07.027
5. Abdel-Razek W, Waked I. Optimal therapy in genotype 4 chronic hepatitis C: finally cured? Liver Int 2015; 35(Suppl. 1): 27–34. doi: 10.1111/liv.12724
6. Gaetano JN. Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug Healthc Patient Saf 2014; 6: 37–45.
7. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100–7.
8. Mangia Alessandra, Piazzolla Valeria. Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies. Dig Liver Dis 2014; 46: S179–85.
9. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014; 61: 373–95doi: 10.1016/j.jhep.2014.05.001 Epub 2014 May 10.
10. De ledinghen V, Vergniol J. Transient elastography (FibroScan). Gastroenterol Clin Biol 2008; 6(Suppl. 1): 58–67.
11. Vallet-Pichard A, Mallet V, Pol S. FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV infected patients. Hepatology 2006; 44: 769; author reply 769–770.
12. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932–54. doi: 10.1002/hep.27950 Epub 2015 Aug 4.
13. Derbala MF, Al Kaabi SR, El Dweik NZ, et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006; 12: 5692–8.
14. Esmat G, Mohamed MK, Abdel Hamid M, et al. The impact of steatosis on baseline characteristic and end of treatment response for chronic hepatitis(C) genotype 4 patients treated with interferon. J Hepatol 2003; 38(Suppl. 2): 139.
15. Thakeb F, Omar M, Bilharz T, Awady M, Isshak S. Randomized controlled trial of peginterferon alfa- 2a plus ribavirin for chronic hepatitis C virus-genotype 4 among Egyptian patients. Hepatology 2003; 38: 278A.
16. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878–87.
17. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013; 58: 583–92.
18. Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 2015; 63: 581–5. doi: 10.1016/j.jhep.2015.04.023 Epub 2015 May
19. Tapper EB, Bacon BR, Curry MP, et al. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat 2017; 24: 22–7.
20. Reddy KR, Lim JK, Kuo A, et al. All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. Aliment Pharmacol Ther 2017; 45: 115–26.
21. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401–8.
22. Lalezari JP, Nelson DR, Hyland RH, et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naïve patients with HCV infection: the QUANTUM study. J Hepatol 2013; 58: S236.
23. Osinusi A, Meissner EG, Bon D, et al. High efficacy of sofosbuvir in combination with weight based ribavirin for 24 weeks in difficult to treat HCV infected genotype-1 patients. In: 20th conference on retroviruses and opportunistic infections, Abstract 157B. Atlanta (GA); March 3–6, 2013.
24. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867–77.
25. Serfaty L. How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals. Liver Int 2015; 35(Suppl. 1): 18–20. doi: 10.1111/liv.12722
26. Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015; 62: 1040–6.